88328
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 1
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.509968942
- umap2_2d
- 2.373703632
- umap1_3d
- -0.331039532
- umap2_3d
- 3.569436666
- umap3_3d
- -1.817058267
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- INTERFERON_ALPHA_RESPONSE+0.490
- G2M_CHECKPOINT+0.460
- MITOTIC_SPINDLE+0.340
- MYC_TARGETS_V1+0.300
- DNA_REPAIR+0.270
- MYC_TARGETS_V2+0.210
- INTERFERON_GAMMA_RESPONSE+0.180
- OXIDATIVE_PHOSPHORYLATION+0.170
- PEROXISOME+0.160
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- ANGIOGENESIS-0.420
- TNFA_SIGNALING_VIA_NFKB-0.410
- IL6_JAK_STAT3_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.360
- ESTROGEN_RESPONSE_EARLY-0.330
- HYPOXIA-0.330
- COAGULATION-0.320
- MYOGENESIS-0.320
- ESTROGEN_RESPONSE_LATE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d01f4531-b145-414b-bc1c-0f1a148b771e | — | — | 0.885 |
| 2 | GSM6454749 | — | F | 0.864 |
| 3 | R160 | — | — | 0.858 |
| 4 | MNG274 | — | — | 0.857 |
| 5 | 48507_S107 | — | cohortMD1 | 0.855 |
| 6 | BS_TW8DQH8J | medulloblastoma | — | 0.852 |
| 7 | TCGA-C8-A27A-01A-11R-A169-07 | — | B | 0.846 |
| 8 | BS_TGS109T3 | high-grade glioma | — | 0.844 |
| 9 | TCGA-34-5231-01A-21R-1820-07 | — | cohortSQ2 | 0.837 |
| 10 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |